查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592051

克拉伯氏症治療市場：按疾病類型、治療方法和分銷管道分類 - 全球預測 2025-2030 年

Krabbe Disease Treatment Market by Disease Type (Infantile, Late-onset), Treatment (Anticonvulsant Agents, Bone Marrow Transplantation, Muscle Relaxer Drugs), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

克拉伯疾病治療市場2023年估值為17.2億美元，預計到2024年將達到18.3億美元，複合年成長率為6.49%，到2030年預計將達到26.8億美元。

克拉伯氏症是一種罕見且往往致命的遺傳性疾病，影響神經系統，由於其複雜性和有限的治療選擇而日益成為醫學研究的焦點。使用的主要治療方法是造血幹細胞移植（HSCT）、酵素替代療法和基因療法，但由於這些治療方法的有效性和可用性有限，市場需求仍然很高。這種未滿足的需求，加上生物技術和醫學的進步，激發了人們對開發更有效、更容易獲得的解決方案的興趣。關鍵的成長要素包括疾病意識和診斷的提高、基因研究的進步以及政府對罕見疾病的支持政策。最新的機會在於 CRISPR 等基因編輯技術和新型藥物配方的進步，為突破性治療和改善患者的生活品質提供了潛力。然而，這個市場面臨重大挑戰，包括高昂的研發成本、與罕見疾病相關的監管複雜性以及有限的患者群。為了克服這些限制，公司可以專注於聯合研究計劃以及與學術機構的夥伴關係。個人化醫療的創新舉措，特別是根據基因譜進行個人化治療，是一個令人興奮的領域，具有成長和差異化的潛力。市場的性質仍然充滿挑戰和前景，其特點是技術快速進步以及物流和財務障礙較高。成功的市場進入和領導地位需要對研發進行策略性投資，對新的監管要求做出敏捷響應，並且對患者的旅程有深入的了解，以熟練地解決關鍵的未滿足的需求。持續進行市場研究以監測技術趨勢、政策轉變和競爭舉措對於克拉伯氏症治療市場的定位和持續成長至關重要。

主要市場統計
基準年[2023] 17.2億美元
預測年份 [2024] 18.3億美元
預測年份 [2030] 26.8億美元
複合年成長率（%） 6.49%

市場動態：揭示快速發展的克拉伯氏症治療市場的關鍵市場洞察

克拉伯氏症治療市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 克拉伯氏症在全球的盛行率不斷上升
    • 基因治療和幹細胞移植研究的增加
    • 政府和私人努力提高對遺傳疾病的認知
  • 市場限制因素
    • 克拉伯氏症的治療高成本
  • 市場機會
    • 克拉伯氏症的診斷和治療進展
    • 擴大克拉伯氏症研究的有利資金狀況
  • 市場問題
    • 克拉伯氏症檢測與治療的倫理問題

波特五力：開拓克拉伯氏症治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解克拉伯氏症治療市場的外在影響

外部宏觀環境因素在塑造克拉伯氏症治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解克拉伯氏症治療市場的競爭格局

對克拉伯病治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣：克拉伯氏症治療市場供應商的績效評估

FPNV定位矩陣是評估克拉伯氏症治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：制定克拉伯氏症治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，克拉伯氏症治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

它也回答重要問題，幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 克拉伯氏症的發生率在全球範圍內增加
      • 增加基因治療和幹細胞移植研究
      • 政府和私人計劃提高人們對遺傳疾病的認知
    • 抑制因素
      • 治療克拉伯氏症的高昂費用
    • 機會
      • 克拉伯氏症的診斷和治療進展
      • 擴大克拉伯氏症研究的有利資金籌措狀況
    • 任務
      • 克拉伯氏症檢測與治療的倫理問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章克拉伯氏症治療市場：依疾病類型

  • 介紹
  • 幼兒期
  • 後天性

第7章克拉伯氏症治療市場：依治療分類

  • 介紹
  • 抗驚厥藥
  • 骨髓移植
  • 肌肉鬆弛劑

第8章克拉伯氏症治療市場：依通路

  • 介紹
  • 電子商務
  • 醫院藥房
  • 零售藥房

第9章 美洲克拉伯氏症治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太克拉伯症治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲克拉伯病治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Acorda Therapeutics Inc.
  • Apteeus SAS
  • Centogene NV
  • Forge Biologics, Inc.
  • Gain Therapeutics, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • M6P Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Pfizer Inc.
  • Polaryx Therapeutics, Inc
  • Polpharma
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharmaceuticals
Product Code: MRR-C002B1C9976C

The Krabbe Disease Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.83 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 2.68 billion by 2030.

Krabbe Disease, a rare and often fatal genetic disorder affecting the nervous system, is increasingly becoming a focal point in healthcare research due to its complexity and limited treatment options. The treatment landscape primarily involves the application of hematopoietic stem-cell transplantation (HSCT), enzyme replacement therapies, and gene therapies, yet the market necessity remains high due to the limited efficacy and availability of these treatments. This unmet need, combined with advancements in biotech and pharmaceuticals, has sparked interest in the development of more effective and accessible solutions. Key growth influencers include increasing awareness and diagnosis of the disease, advances in genetic research, and supportive government policies aimed at rare diseases. Latest opportunities lie in the progression of gene-editing technologies like CRISPR and novel drug formulations, providing potential for groundbreaking treatments and improved quality of life for patients. Nevertheless, the market faces significant challenges, including high R&D costs, regulatory complexities associated with rare diseases, and a limited patient pool, which can deter investment. To overcome these limitations, businesses can focus on collaborative research initiatives and partnerships with academic institutions, which can provide access to cutting-edge technology and shared resources. Innovative efforts in personalized medicine, particularly in tailoring treatments based on genetic profiles, represent an exciting area of potential growth and differentiation. The nature of the market remains both challenging and promising, characterized by rapid technological advances alongside logistical and financial hurdles. Successful market entries and leadership would likely require strategic investment in R&D, agile adaptation to emerging regulatory requirements, and a robust understanding of the patient journey to address critical unmet needs expertly. Engaging in continuous market research to monitor technological trends, policy shifts, and competitive movements will be essential for positioning and sustaining growth in the Krabbe Disease treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.83 billion
Forecast Year [2030] USD 2.68 billion
CAGR (%) 6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Krabbe Disease Treatment Market

The Krabbe Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of Krabbe disease worldwide
    • Rise in gene therapy and stem cell transplantation research
    • Government and private initiatives to raise awareness about inherited disorders
  • Market Restraints
    • High cost associated with treatment for Krabbe disease
  • Market Opportunities
    • Advancements in the diagnosis and treatment of Krabbe disease
    • Favorable funding landscape for expanding research on krabbe disease
  • Market Challenges
    • Ethical issues with testing and treatment for Krabbe disease

Porter's Five Forces: A Strategic Tool for Navigating the Krabbe Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Krabbe Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Krabbe Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Krabbe Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Krabbe Disease Treatment Market

A detailed market share analysis in the Krabbe Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Krabbe Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Krabbe Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Krabbe Disease Treatment Market

A strategic analysis of the Krabbe Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Krabbe Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acorda Therapeutics Inc., Apteeus SAS, Centogene N.V., Forge Biologics, Inc., Gain Therapeutics, Inc., GlaxoSmithKline Plc, Johnson & Johnson, M6P Therapeutics, Neurogene Inc., Novartis AG, Pfizer Inc., Polaryx Therapeutics, Inc, Polpharma, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Krabbe Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Infantile and Late-onset.
  • Based on Treatment, market is studied across Anticonvulsant Agents, Bone Marrow Transplantation, and Muscle Relaxer Drugs.
  • Based on Distribution Channel, market is studied across E-commerce, Hospital Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Krabbe disease worldwide
      • 5.1.1.2. Rise in gene therapy and stem cell transplantation research
      • 5.1.1.3. Government and private initiatives to raise awareness about inherited disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with treatment for Krabbe disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in the diagnosis and treatment of Krabbe disease
      • 5.1.3.2. Favorable funding landscape for expanding research on krabbe disease
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues with testing and treatment for Krabbe disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Krabbe Disease Treatment Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Infantile
  • 6.3. Late-onset

7. Krabbe Disease Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Anticonvulsant Agents
  • 7.3. Bone Marrow Transplantation
  • 7.4. Muscle Relaxer Drugs

8. Krabbe Disease Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospital Pharmacies
  • 8.4. Retail Pharmacies

9. Americas Krabbe Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Krabbe Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Krabbe Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acorda Therapeutics Inc.
  • 3. Apteeus SAS
  • 4. Centogene N.V.
  • 5. Forge Biologics, Inc.
  • 6. Gain Therapeutics, Inc.
  • 7. GlaxoSmithKline Plc
  • 8. Johnson & Johnson
  • 9. M6P Therapeutics
  • 10. Neurogene Inc.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Polaryx Therapeutics, Inc
  • 14. Polpharma
  • 15. Sanofi S.A.
  • 16. Takeda Pharmaceutical Company Limited
  • 17. Teva Pharmaceutical Industries Ltd.
  • 18. UCB Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. KRABBE DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. KRABBE DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. KRABBE DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. KRABBE DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. KRABBE DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. KRABBE DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY INFANTILE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY LATE-ONSET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY ANTICONVULSANT AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY MUSCLE RELAXER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL KRABBE DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES KRABBE DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM KRABBE DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. KRABBE DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. KRABBE DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023